All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Kura Oncology, Syndax, Abbvie, Thermo Fisher and Johnson & Johnson. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View AML content recommended for you
Featured:
Do you know... Which of the following best describes the current key clinical limitations of first-generation menin inhibitors in the treatment of AML?
The AML Hub was pleased to speak with Joshua Zeidner, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, US. We asked, What progress has been made with first-generation menin inhibitors in AML, and what needs remain?
What progress has been made with first-generation menin inhibitors in AML, and what needs remain?
During this interview, Zeidner discusses the clinical advances achieved with first-generation menin inhibitors, revumenib and ziftomenib, for patients with relapsed/refractory (R/R) KMT2A-rearranged (KMT2Ar) or NPM1-mutated (NPM1m) AML, and he highlights limited durations of response (DoRs) and acquired resistance as remaining unmet needs in this space. He also explores the potential of next-generation menin inhibitors, including bleximenib and enzomenib, and combination strategies to address the ongoing limitations.
This educational resource is independently supported by Johnson & Johnson. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
Your opinion matters
Where do you see the greatest future value for NGS-based MRD assessment in AML/MDS?